Cardiome lays off 85% of workforce, stock trades halted
This article was originally published in Scrip
Executive Summary
Trading of Cardiome Pharma stock was halted on 9 July when the Canadian company announced that it would lay off 85% of its workforce in the wake of Merck's decision in March to discontinue development of an oral version of Brinavess (vernakalant) for long-term prevention of atrial fibrillation recurrence (scripintelligence.com, 20 March 2012).